20.10
price down icon0.54%   -0.11
after-market  After Hours:  20.105  0.005   +0.02%
loading
Fresenius Medical Care AG & Co. KGaA ADR stock is currently priced at $20.10, with a 24-hour trading volume of 305.42K. It has seen a -0.54% decreased in the last 24 hours and a +6.29% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $20.26 pivot point. If it approaches the $20.05 support level, significant changes may occur.
Previous Close:
$20.21
Open:
$20.09
24h Volume:
305.42K
Market Cap:
$11.80B
Revenue:
$21.06B
Net Income/Loss:
$540.03M
P/E Ratio:
24.64
EPS:
0.8156
Net Cash Flow:
$2.10B
1W Performance:
+2.87%
1M Performance:
+6.29%
6M Performance:
+21.38%
1Y Performance:
-13.14%
1D Range:
Value
$19.91
$20.15
52W Range:
Value
$16.37
$27.71

Fresenius Medical Care AG & Co. KGaA ADR Stock (FMS) Company Profile

Name
Name
Fresenius Medical Care AG & Co. KGaA ADR
Name
Phone
49 6172 609 0
Name
Address
Else-Kröner Strasse 1, Bad Homburg
Name
Employee
112,134
Name
Twitter
@fmc_ag
Name
Next Earnings Date
Name
Latest SEC Filings
Name
FMS's Discussions on Twitter

Fresenius Medical Care AG & Co. KGaA ADR Stock (FMS) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-08-24 Downgrade Morgan Stanley Equal-Weight → Underweight
Nov-24-23 Upgrade HSBC Securities Reduce → Hold
Nov-17-23 Upgrade Societe Generale Hold → Buy
Aug-14-23 Downgrade UBS Buy → Neutral
Aug-01-23 Resumed Citigroup Neutral
Jul-12-23 Initiated Goldman Buy
Mar-07-23 Initiated Bernstein Mkt Perform
Jan-03-23 Downgrade Jefferies Buy → Underperform
Oct-26-22 Downgrade Deutsche Bank Hold → Sell
Oct-18-22 Initiated Morgan Stanley Equal-Weight
Oct-10-22 Downgrade Jefferies Buy → Hold
Jun-27-22 Upgrade Jefferies Underperform → Buy
Feb-11-22 Downgrade Jefferies Hold → Underperform
Nov-23-21 Initiated HSBC Securities Hold
Nov-11-21 Upgrade Jefferies Underperform → Hold
Feb-04-21 Downgrade JP Morgan Overweight → Neutral
Feb-03-21 Downgrade Deutsche Bank Buy → Hold
Aug-05-20 Downgrade Jefferies Buy → Hold
May-20-20 Upgrade Morgan Stanley Underweight → Equal-Weight
Jan-21-20 Upgrade Jefferies Hold → Buy
Jun-20-19 Upgrade Barclays Equal Weight → Overweight
Dec-10-18 Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-26-18 Upgrade UBS Neutral → Buy
Aug-28-18 Upgrade HSBC Securities Hold → Buy
Jul-05-18 Downgrade Credit Suisse Outperform → Neutral
Jan-04-18 Upgrade UBS Sell → Neutral
Dec-11-17 Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-01-16 Reiterated RBC Capital Mkts Sector Perform
Sep-06-16 Upgrade Citigroup Neutral → Buy
Jul-08-16 Upgrade Jefferies Underperform → Hold
Jan-04-16 Upgrade JP Morgan Neutral → Overweight
Nov-04-15 Reiterated RBC Capital Mkts Sector Perform
Sep-03-15 Upgrade Goldman Neutral → Buy
Aug-13-15 Downgrade Societe Generale Buy → Hold
Jul-31-15 Reiterated RBC Capital Mkts Sector Perform
Aug-02-13 Reiterated Feltl & Co. Hold
Jan-14-13 Upgrade HSBC Securities Neutral → Overweight
View All

Fresenius Medical Care AG & Co. KGaA ADR Stock (FMS) Financials Data

Fresenius Medical Care AG & Co. KGaA ADR (FMS) Revenue 2024

FMS reported a revenue (TTM) of $21.06 billion for the quarter ending December 31, 2023, a +3.17% rise year-over-year.
loading

Fresenius Medical Care AG & Co. KGaA ADR (FMS) Net Income 2024

FMS net income (TTM) was $540.03 million for the quarter ending December 31, 2023, a -23.62% decrease year-over-year.
loading

Fresenius Medical Care AG & Co. KGaA ADR (FMS) Cash Flow 2024

FMS recorded a free cash flow (TTM) of $2.10 billion for the quarter ending December 31, 2023, a +38.28% increase year-over-year.
loading

Fresenius Medical Care AG & Co. KGaA ADR (FMS) Earnings per Share 2024

FMS earnings per share (TTM) was $0.9199 for the quarter ending December 31, 2023, a -23.49% decline year-over-year.
loading
Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, hospitalist and intensivist, medical cost management, ambulatory surgery center, health plan, urgent care, physician nephrology and cardiology, and ambulant treatment services. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; and offers non-dialysis products, including acute cardiopulmonary and apheresis products. The company sells its products to clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2017, it operated 3,752 outpatient dialysis clinics in approximately 50 countries. The company has operations in Germany, the United States, and internationally. Fresenius Medical Care AG & Co. KGaA was founded in 1996 and is headquartered in Bad Homburg, Germany.
medical_care_facilities DVA
$133.51
price up icon 0.56%
medical_care_facilities UHS
$166.06
price up icon 0.58%
medical_care_facilities THC
$96.13
price down icon 1.42%
medical_care_facilities CHE
$560.42
price down icon 2.25%
medical_care_facilities EHC
$82.47
price down icon 0.31%
Cap:     |  Volume (24h):